Pharmacokinetics and Metabolic Transformation Pathways
Understanding the absorption, distribution, metabolism, and excretion (ADME) of duloxetine API is essential for safe dosing. The compound is acid-labile, meaning it degrades rapidly in the low pH environment of the stomach into 1-naphthol, a toxic byproduct. To prevent this, the active ingredient is always formulated as enteric-coated pellets within a capsule. Once it reaches the alkaline environment of the small intestine, it is absorbed with a bioavailability of approximately 80%.
Metabolism occurs extensively in the liver, primarily mediated by the cytochrome P450 enzymes CYP1A2 and CYP2D6. The process involves hydroxylation at various positions on the naphthyl ring, followed by conjugation with glucuronide or sulfate for excretion. Because duloxetine is both a substrate and a moderate inhibitor of CYP2D6, clinicians must be wary of drug-drug interactions with other medications processed by the same enzyme. The elimination half-life of the drug is approximately 12 hours, allowing for once-daily dosing in most adult populations. Steady-state plasma concentrations are typically reached within three days of continuous administration.